Robert B. Bazemore - 16 Dec 2025 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)

Role
Director
Signature
/s/ Abizer Gaslightwala, as Attorney-in-Fact
Issuer symbol
AKTX
Transactions as of
16 Dec 2025
Net transactions value
+$62,499
Form type
4
Filing time
18 Dec 2025, 21:56:12 UTC
Previous filing
23 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bazemore Robert B Director C/O AKARI THERAPEUTICS PLC, 401 EAST JACKSON STREET, SUITE 3300, TAMPA /s/ Abizer Gaslightwala, as Attorney-in-Fact 18 Dec 2025 0001620152

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKTX Warrants to purchase American Depositary Shares ("ADRs") Purchase +123,731 123,731 16 Dec 2025 American Depositary Shares representing Ordinary Shares 123,731 $0.3883 Direct F1, F2, F3, F4
transaction AKTX Pre-Funded Warrants to purchase ADRs Purchase $50,000 +123,731 $0.4041 123,731 16 Dec 2025 American Depositary Shares representing Ordinary Shares 123,731 $0.000000 Direct F1, F2, F3, F4, F7
transaction AKTX Warrants to purchase ADRs Purchase +30,932 30,932 16 Dec 2025 American Depositary Shares representing Ordinary Shares 30,932 $0.3883 Direct F1, F5, F6
transaction AKTX Pre-Funded Warrants to purchase ADRs Purchase $12,500 +30,932 $0.4041 30,932 16 Dec 2025 American Depositary Shares representing Ordinary Shares 30,932 $0.000000 Direct F1, F5, F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer.
F2 On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 123,731 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 123,731 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended.
F3 The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised.
F4 The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041.
F5 On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 30,932 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 32,191 ADSs (the "Note Exchange Unregistered Warrants").
F6 The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised.
F7 Conversion Exercise Price of Security is $0.00001

Remarks:

See Exhibit 24 - Power of Attorney